Skip to main content

MoneyWorks4Me

Glenmark Pharmaceuticals informs about press release

19 Feb 2018 Evaluate

Glenmark Pharmaceuticals has informed about press release titled ‘Glenmark Pharmaceuticals Presents New Data on GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting’.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1778.25
Dr. Reddys Labs. 1350.20
Cipla 1380.00
Lupin 2009.00
Zydus Lifesciences 1244.00
View more..